![](/img/cover-not-exists.png)
Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial
Solomon, S R, Sizemore, C A, Zhang, X, Brown, S, Holland, H K, Morris, L E, Bashey, AVolume:
49
Language:
english
Journal:
Bone Marrow Transplantation
DOI:
10.1038/bmt.2014.2
Date:
May, 2014
File:
PDF, 546 KB
english, 2014